Statin trials and goals of cholesterol-lowering therapy

Editorial

S M Grundy. Circulation. 1998.

. 1998 Apr 21;97(15):1436-9.

doi: 10.1161/01.cir.97.15.1436.

No abstract available

Comment in

Goals for cholesterol lowering.
Stankler L. Stankler L. Circulation. 1999 May 11;99(18):2477. Circulation. 1999. PMID: 10318741 No abstract available.

Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS).
[No authors listed] [No authors listed] Circulation. 1998 Apr 21;97(15):1440-5. doi: 10.1161/01.cir.97.15.1440. Circulation. 1998. PMID: 9576423 Clinical Trial.
Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial.
Sacks FM, Moyé LA, Davis BR, Cole TG, Rouleau JL, Nash DT, Pfeffer MA, Braunwald E. Sacks FM, et al. Circulation. 1998 Apr 21;97(15):1446-52. doi: 10.1161/01.cir.97.15.1446. Circulation. 1998. PMID: 9576424 Clinical Trial.
Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S).
Pedersen TR, Olsson AG, Faergeman O, Kjekshus J, Wedel H, Berg K, Wilhelmsen L, Haghfelt T, Thorgeirsson G, Pyörälä K, Miettinen T, Christophersen B, Tobert JA, Musliner TA, Cook TJ. Pedersen TR, et al. Circulation. 1998 Apr 21;97(15):1453-60. doi: 10.1161/01.cir.97.15.1453. Circulation. 1998. PMID: 9576425 Clinical Trial.